Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Squeeze the dropper to draw up the serum to start applying it to your face
Glob J Health Sci
About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
Key Insights & Takeaways: 1 A Paradigm Shift Meets Prescriber Inertia: Despite being a first-in-class mechanismapproved in 2024 as the only novel schizophrenia therapy in decadesCOBENFY (xanomeline and trospium chloride) US HCP faces deeply ingrained D2 prescribing habits, as noted by BMS leadership
Poulter, S
doi: 10.3233/JPD-171068 201 VertesR
